Clinical research is rapidly advancing in using psychedelic drugs to treat opioid addiction. However, psychedelics can also reduce opioid-related deaths as a SUBSTITUTE for opioids.
Clinical research is rapidly advancing in using psychedelic drugs to treat opioid addiction. However, psychedelics can also reduce opioid-related deaths as a SUBSTITUTE for opioids.
Compass Pathways acquires an unspecified IP portfolio of psychedelic and emphathogenic substances.
Wesana looks to expand its TBI-based psychedelics research into MDMA, with a new research partnership with MAPS.
Atai affiliate, Perception Neuroscience is commencing a Phase 2a clinical trial of an R-ketamine medication for the treatment of depression.
Big Pharma's business model for drug development is all about maximizing profits, not health. Psychedelic medicine can maximize profits AND health.
Atai Life Sciences seeks to integrate digital therapeutics into ketamine-based treatment for TRD, via its digital therapeutic platform, Introspect Digital Therapeutics.
Psychedelics media star, Hamilton Morris is joining Compass Pathways as a full-time consultant on psychedelics research.
Wesana Health closes on its acquisition of PsyTech, solidifying its business model as it seeks a U.S. listing.
Novamind commences formal trading on the OTCQB under the symbol "NVMDF".
Field Trip will focus on Treatment-Resistant Depression and Postpartum Depression as indications for drug development of FT-104.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now